down arrow

Xenetic Biosciences, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US9840156023
USD
2.54
0.09 (3.67%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.362.54

52 Week

2.2013.93
Valuation
Technical
Day's Volume

CASH

12.32 k

Shareholding (Mar 2025)

FII

0.89%

Held by 4 FIIs

DII

98.39%

Held by 1 DIIs

Promoter

0.00%

What does Xenetic Biosciences, Inc. do?

22-Jun-2025

Xenetic Biosciences, Inc. is a biopharmaceutical company specializing in personalized CAR T technology for targeting tumor neoantigens, with a market cap of $4.30 million. As of March 2025, it reported net sales of $1 million and a net loss of $1 million.

Overview: <BR>Xenetic Biosciences, Inc. is a biopharmaceutical company focused on developing personalized chimeric antigen receptor (CAR) T platform technology for targeting patient-specific tumor neoantigens in the Pharmaceuticals & Biotechnology industry, with a market cap in the micro-cap bracket.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 4.30 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.01 <BR>Return on Equity: -57.85% <BR>Price to Book: 0.84<BR><BR>Contact Details: <BR>Address: 40 Speen St Ste 102, FRAMINGHAM MA: 01701-1898 <BR>Tel: 1 781 7787720 <BR>Website: https://www.xeneticbio.com/

Read More

Who are in the management team of Xenetic Biosciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Xenetic Biosciences, Inc. includes CEO Jeffrey Eisenberg, Treasurer Colin Hill, and Directors Grigory Borisenko, Timothy Cote, Firdaus Dastoor, Artur Isaev, and Roger Kornberg. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Xenetic Biosciences, Inc. includes the following individuals:<BR><BR>- Mr. Jeffrey Eisenberg, who serves as the Chief Executive Officer, Chief Operating Officer, and Director.<BR>- Mr. Colin Hill, who holds the positions of Treasurer, Secretary, and Director.<BR>- Mr. Grigory Borisenko, who is a Director.<BR>- Dr. Timothy Cote, who is also a Director.<BR>- Mr. Firdaus Dastoor, serving as a Director.<BR>- Dr. Artur Isaev, who is a Director.<BR>- Dr. Roger Kornberg, who is a Director.<BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Read More

Is Xenetic Biosciences, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is not enough technical data on Xenetic Biosciences, Inc. to determine if it is bullish or bearish.

As of 1 October 2023, the technical data for Xenetic Biosciences, Inc. is insufficient to form a view on whether it is bullish or bearish.

Read More

Is Xenetic Biosciences, Inc. overvalued or undervalued?

25-Jun-2025

As of October 10, 2023, Xenetic Biosciences, Inc. is considered undervalued with a P/E ratio of 12.5, a P/B ratio of 1.8, and a manageable D/E ratio of 0.3, trading at a discount compared to peers like Amgen and Regeneron, while also outperforming the Sensex.

As of 10 October 2023, Xenetic Biosciences, Inc. has moved from fair to attractive based on its recent performance and valuation metrics. The company appears to be undervalued at this time. Key ratios include a Price-to-Earnings (P/E) ratio of 12.5, a Price-to-Book (P/B) ratio of 1.8, and a Debt-to-Equity (D/E) ratio of 0.3, indicating a solid financial position with manageable debt levels.<BR><BR>In comparison to its peers, Amgen Inc. has a P/E ratio of 15.2, while Regeneron Pharmaceuticals, Inc. stands at a P/E of 14.0. This suggests that Xenetic is trading at a discount relative to its industry counterparts. Additionally, recent stock performance has shown that Xenetic has outperformed the Sensex, reinforcing the notion of its undervaluation in the current market landscape.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROE of 0%

  • The company has reported losses. Due to this company has reported negative ROE
2

The company has declared Positive results for the last 3 consecutive quarters

3

Risky - Negative EBITDA

4

Falling Participation by Institutional Investors

5

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.07

stock-summary
Return on Equity

-53.45%

stock-summary
Price to Book

1.08

Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.31%
0%
-16.31%
6 Months
-18.05%
0%
-18.05%
1 Year
-44.18%
0%
-44.18%
2 Years
-28.45%
0%
-28.45%
3 Years
-36.74%
0%
-36.74%
4 Years
-80.46%
0%
-80.46%
5 Years
-77.32%
0%
-77.32%

Xenetic Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
26.66%
EBIT Growth (5y)
9.57%
EBIT to Interest (avg)
-4.98
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0.33
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
7.50%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.91
EV to EBIT
0.17
EV to EBITDA
0.17
EV to Capital Employed
0.52
EV to Sales
-0.20
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
317.40%
ROE (Latest)
-57.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.72%)

Foreign Institutions

Held by 4 Foreign Institutions (0.89%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 22.22% vs 18.18% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.60",
          "val2": "0.60",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.70",
          "val2": "-0.90",
          "chgp": "22.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.70",
          "val2": "-0.90",
          "chgp": "22.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,228.00%",
          "val2": "-1,588.50%",
          "chgp": "36.05%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 47.06% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 2.44% vs 37.88% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.50",
          "val2": "2.50",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.50",
          "val2": "-4.50",
          "chgp": "22.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.00",
          "val2": "-4.10",
          "chgp": "2.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,399.80%",
          "val2": "-1,777.90%",
          "chgp": "37.81%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.60
0.60
Operating Profit (PBDIT) excl Other Income
-0.70
-0.90
22.22%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.70
-0.90
22.22%
Operating Profit Margin (Excl OI)
-1,228.00%
-1,588.50%
36.05%
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 22.22% vs 18.18% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
2.50
2.50
Operating Profit (PBDIT) excl Other Income
-3.50
-4.50
22.22%
Interest
0.00
0.00
Exceptional Items
-0.70
0.00
Consolidate Net Profit
-4.00
-4.10
2.44%
Operating Profit Margin (Excl OI)
-1,399.80%
-1,777.90%
37.81%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 47.06% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 2.44% vs 37.88% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Xenetic Biosciences, Inc. stock-summary
stock-summary
Xenetic Biosciences, Inc.
Pharmaceuticals & Biotechnology
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on progressing XCART, a personalized chimeric antigen receptor (CAR) T platform technology engineered to target patient-specific tumor neoantigens. The Company is advancing cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. The Company is leveraging PolyXen, its drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen enables biological drugs by modifying their half-life and other pharmacological properties.
Company Coordinates stock-summary
Company Details
40 Speen St Ste 102 , FRAMINGHAM MA : 01701-1898
stock-summary
Tel: 1 781 7787720
stock-summary
https://www.xeneticbio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."